tiprankstipranks
Starpharma’s DEP® SN38 Shows Promising Cancer Treatment Results
Company Announcements

Starpharma’s DEP® SN38 Shows Promising Cancer Treatment Results

Starpharma Holdings Limited (AU:SPL) has released an update.

Pick the best stocks and maximize your portfolio:

Starpharma Holdings Limited’s DEP® SN38 shows promising results in treating advanced colorectal and ovarian cancers, as presented at a recent cancer conference. The drug demonstrated sustained disease control and improved quality of life for patients with reduced toxicity compared to standard treatments. These promising Phase 1/2 trial results position DEP® SN38 as a strong candidate for further development and potential commercialization.

For further insights into AU:SPL stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskStarpharma CEO Receives Major Performance Rights Issuance
TipRanks Australian Auto-Generated NewsdeskStarpharma Issues Unquoted Securities to Boost Employee Incentives
TipRanks Australian Auto-Generated NewsdeskStarpharma Holdings Reports Successful AGM Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App